Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty — HERA

Aging Frailty Clinical Trial

Official title:
Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty

Status Completed

Clinical Trial Summary

This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response.

Clinical Trial Description

A pilot phase will consist of a 3 subject safety run-in, followed by 20 subject randomized phase to evaluate influenza vaccine response at 1 week and 4 weeks post infusion of Lomecel-B (Formerly LMSCs). This will be followed by a double-blinded, randomized, placebo-controlled phase. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02982915
Study type	Interventional
Source	Longeveron Inc.
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	November 2016
Completion date	September 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06063590` - A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients	Phase 1/Phase 2
Completed	`NCT03071835` - A Comparative Study of Subjects Past Their Final Follow-ON Visit
Completed	`NCT04314011` - Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty	Phase 1/Phase 2
Completed	`NCT03169231` - Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty	Phase 2